Otsuka eyes early filing of IgAN drug after phase 3 readout

Otsuka eyes early filing of IgAN drug after phase 3 readout

Submitted by admin on October 22, 2024 - 11:19am
Source: 
Pharmaphorum
News Tags: 
Otsuka
anti-APRIL
sibeprenlimab
IgA nephropathy
clinical trials
Headline: 
Otsuka eyes early filing of IgAN drug after phase 3 readout
snippet: 

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.

Do Not Allow Advertisers to Use My Personal information